Project Summary
G protein-coupled receptors (GPCRs) can be activated by partial agonists, resulting in submaximal signaling
with reduced side effects, compared to the full agonist. Increased studies have indirectly demonstrated that
partial agonists stabilize intermediate conformational states between the inactive and fully activated states with
a reduced heterotrimeric Gabg protein coupling activity from the fully activated state. Due to the technical hurdles
in delineating GPCR conformational states and populating individual intermediate states to study them
individually, a mechanistical understanding of partial agonism signaling has been challenging. By creating
conformation-biased mutants, we identified five adenosine A2A receptor (A2AR) conformational states, including
two inactive states (S1 and S2), two intermediate states (S3 and S4), and a fully active state (S5), using 19F
nuclear magnetic resonance (NMR) spectroscopy. This result is a significant advancement to previous research.
The R291A mutant predominantly accumulates the intermediate S4 state while the R291AR293A mutant
populates both intermediate S3 state and the full activated state S5. This finding enables us to study the roles
of these intermediates and their complexes. We will use these two mutants to examine the roles of intermediate
states S3 and S4 and their interactions with G proteins and consequent signaling effects.
In Aim 1, we will characterize whether and how the intermediate states S3 and S4 interact with Gasbg. These
characterizations will include the study of conformational transitions and dynamics of intermediate states and
the effects of Gasbg and ligands on their transitions and dynamics. In Aim 2, we will map the conformational
states of the Gas and determine its intermediate states that interact with the S3 and S4 states of the A2AR. In
Aim 3, we will determine if the intermediate states S3 and S4 of the A2AR induce Gasbg states that are competent
for GTP hydrolysis, G protein dissociation, and contribution to submaximal signaling without the S5 state being
involved. We expect to correlate conformational and dynamic characteristics of the intermediate states of the
A2AR and Gas protein created from Aims 1 and 2 to the signaling efficacies of conformation-biased mutants with
ligand stoichiometries, measured in Aim 3.
The completion of this proposed project will advance our understanding of the roles that intermediate
conformations play in GPCR signaling, lead to a conceptual innovation in understanding receptor activation
beyond a simple two-state model, and potentially guide drug design based on GPCR and G protein
conformational responses to ligands. Moreover, the conformation-biased mutants will guide an approach
development in resolving the structures of intermediate complexes.